CLINICAL TRIALS PROFILE FOR MARINOL
✉ Email this page to a colleague
All Clinical Trials for MARINOL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00079560 ↗ | Comparing the Effects of Smoked and Oral Marijuana in Individuals With HIV/AIDS | Completed | National Institute on Drug Abuse (NIDA) | Phase 1/Phase 2 | 2001-12-01 | Smoked marijuana (MJ) and dronabinol (also known as THC or by the trade name Marinol) are used to increase appetite, food intake, and weight in patients with HIV who experience unintended weight loss. This study will compare the effects of MJ and Marinol use in marijuana smokers who are HIV infected. |
| NCT00153192 ↗ | Study to Evaluate the Efficacy of Dronabinol (Marinol) as Add-On Therapy for Patients on Opioids for Chronic Pain | Completed | Solvay Pharmaceuticals | Phase 2/Phase 3 | 2001-04-01 | The purpose of this research study is to determine if Marinol alleviates pain in patients with chronic pain who are currently taking opioids. The study begins with a 2-hour initial visit followed by three 8-hour appointments at Brigham and Women's Hospital. At each 8-hour visit, patients receive a dose of medication and complete surveys relating to pain. During the first visit a brief examination and a few surveys about pain, quality of life, and medical history are given. The study doctor then determines if the participant continues to qualify for the study. If qualified for the study, patients receive a daily diary to record pain levels and pain medications; this will take about 5 minutes each day. After completion of the diary, patients begin the 8-hour visits. Patients visit the Pain Trials Center three times to receive study medication. After taking the study medication, participants remain in the clinic for 8 hours to complete hourly surveys about pain and pain relief. Subsequent to these visits, patients may enter a 1-month extension where Marinol is taken at home, and pain levels are recorded in a diary. Participants can change the dose of study drug to better control pain and side effects, after speaking with study staff. The study then concludes with a final 30-minute visit to summarize the participant's experience in the clinical trial. |
| NCT00153192 ↗ | Study to Evaluate the Efficacy of Dronabinol (Marinol) as Add-On Therapy for Patients on Opioids for Chronic Pain | Completed | Brigham and Women's Hospital | Phase 2/Phase 3 | 2001-04-01 | The purpose of this research study is to determine if Marinol alleviates pain in patients with chronic pain who are currently taking opioids. The study begins with a 2-hour initial visit followed by three 8-hour appointments at Brigham and Women's Hospital. At each 8-hour visit, patients receive a dose of medication and complete surveys relating to pain. During the first visit a brief examination and a few surveys about pain, quality of life, and medical history are given. The study doctor then determines if the participant continues to qualify for the study. If qualified for the study, patients receive a daily diary to record pain levels and pain medications; this will take about 5 minutes each day. After completion of the diary, patients begin the 8-hour visits. Patients visit the Pain Trials Center three times to receive study medication. After taking the study medication, participants remain in the clinic for 8 hours to complete hourly surveys about pain and pain relief. Subsequent to these visits, patients may enter a 1-month extension where Marinol is taken at home, and pain levels are recorded in a diary. Participants can change the dose of study drug to better control pain and side effects, after speaking with study staff. The study then concludes with a final 30-minute visit to summarize the participant's experience in the clinical trial. |
| NCT00217971 ↗ | Dronabinol Treatment for Marijuana Addiction | Completed | National Institute on Drug Abuse (NIDA) | Phase 2 | 2005-03-01 | The purpose of this study is to determine if dronabinol decreases the symptoms of marijuana addiction and withdrawal. |
| NCT00217971 ↗ | Dronabinol Treatment for Marijuana Addiction | Completed | New York State Psychiatric Institute | Phase 2 | 2005-03-01 | The purpose of this study is to determine if dronabinol decreases the symptoms of marijuana addiction and withdrawal. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MARINOL
Condition Name
Clinical Trial Locations for MARINOL
Trials by Country
Clinical Trial Progress for MARINOL
Clinical Trial Phase
Clinical Trial Sponsors for MARINOL
Sponsor Name
